Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme.
Phase of Trial: Phase I/II
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Ofranergene obadenovec (Primary) ; Bevacizumab
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- Sponsors VBL Therapeutics
- 19 Jun 2017 According to a VBL Therapeutics media release, long-term survival data from this trial will be presented at 2017 BIO International Convention.
- 19 Jun 2017 Long-term survival data from this trial published in a VBL Therapeutics Media Release.
- 06 Jun 2017 Results (n=46) assessing tumour growth of individual patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History